UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 2, 2018

 

 

 

Eloxx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-31326   84-1368850

(State or other jurisdiction

of incorporation)

 

  

(Commission

File Number)

 

  

(IRS Employer

Identification No.)

 

950 Winter Street

Waltham, MA

   02451
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 577-5300

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934(§240.12b-2 of this chapter).

 

Emerging growth company  ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On October 2, 2018, Eloxx Pharmaceuticals, Inc. (the “Company”) presented certain information at the 2018 Cantor Global Healthcare Conference at the InterContinental New York Barclay Hotel in New York City. A copy of the presentation materials is attached hereto as Exhibit 99.1 and is incorporated herein by reference. A live webcast of the meeting was made available to the general public. A copy of the presentation materials may be found at the Company’s website (www.eloxxpharma.com) and clicking the Investor Relations webpage.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, is furnished pursuant to this Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibit 99.1    The Company’s 2018 Cantor Global Healthcare Conference presentation materials dated October 2, 2018.
     
    This exhibit is furnished pursuant to Item 7.01 and shall not be deemed to be “filed.”

 

 

Exhibit No.

  

Description

   
99.1   The Company’s 2018 Cantor Global Healthcare Conference presentation materials dated October 2, 2018.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ELOXX PHARMACEUTICALS, INC.
     
Date: October 2, 2018 By:

/s/ Gregory Weaver 

    Gregory Weaver
    Chief Financial Officer